AVIR

Atea Pharmaceuticals, Inc.

5.80 USD

Last updated Sep 4, 20:06 UTC

Yesterday HIGH

$5.84

Yesterday LOW

$5.64

52w HIGH

$6.45

52w LOW

$2.78

EPS

-0.41

PE

-14.15

Next Earnings

Nov 11, 2026

Overview News Unusual Options Flow Government Trades Fundamentals

Atea Pharmaceuticals, Inc. stock is up 22.11% since 30 days ago. The next earnings date is Nov 11, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 47.73% of the previous 50 September’s closed higher than August. In the last 7 Unusual Options Trades, there were 6 CALLs, 1 PUT. 0% of analysts rate it a buy.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

14 Jul 17:20	16 Oct, 2026	5.00	CALL	485	1829
14 Jul 18:48	16 Oct, 2026	5.00	CALL	667	1829
14 Jul 18:48	16 Oct, 2026	5.00	CALL	400	1829
14 Jul 19:18	16 Oct, 2026	5.00	CALL	322	1829
16 Jul 16:21	16 Oct, 2026	5.00	CALL	712	4243
23 Jul 19:59	16 Oct, 2026	5.00	CALL	314	5244
11 Aug 16:06	17 Dec, 2027	5.00	PUT	306	0

Advanced Data Unlock

Webmaster

Tue Jul 28, 2026

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times
Benzinga Newsdesk

Tue Jul 28, 2026

Atea Pharmaceuticals Says Topline Data From C-BEYOND Phase 3 Trial Of Once-daily Fixed-Dose Combination Of Bemnifosbuvir and Ruzasvir for Chronic Hepatitis C Virus Infection Shows Statistical Non-Inferiority Vs. Fixed-Dose Combination Of Sofosbuvir and Velpatasvir

In the mITT analysis (n=905, cirrhotic and non-cirrhotic), BEM/RZR achieved a 93.9% sustained virologic response (SVR) rate vs. 94.8% for SOF/VEL (Epclusa) at Week 24, encompassing SVR at 12 weeks post-treatment
Webmaster

Tue Jul 28, 2026

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending
Benzinga Newsdesk

Tue Jul 14, 2026

Atea Pharmaceuticals Initiates First-in-human Phase 1 Clinical Trial Of AT-587 For Hepatitis E Virus Infection

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today
Benzinga Insights

Fri Jul 10, 2026

12 Health Care Stocks Moving In Friday's After-Market Session

Gainers Q32 Bio (NASDAQ:QTTB) stock moved upwards by 44.4% to $16.19 during Friday's after-market session. The company's market cap stands at $213.4 million. China Pharma Holding (AMEX:CPHI) shares increased
Benzinga Newsdesk

Thu Jun 25, 2026

Atea Pharma Completes Patient Enrollment In C-FORWARD, Phase 3 Clinical Trial Outside North America, Evaluating Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus Infection

Topline Phase 3 Results from C-FORWARD Expected Around Year-End 2026More Than 880 HCV Treatment-Naïve Patients Enrolled Across 17 Countries Outside North AmericaC-FORWARD and C-BEYOND Represent the First Global Phase 3
Benzinga Newsdesk

Wed May 27, 2026

Atea Pharmaceuticals' BEM/RZR Phase 1 Results Show Low Drug-Drug Interaction Risk With Commonly Used Medications For Hepatitis C Patients
Benzinga Insights

Tue May 12, 2026

Atea Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript
Benzinga Newsdesk

Tue May 12, 2026

Atea Pharmaceuticals Q1 EPS $(0.57) Beats $(0.59) Estimate

Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.59) by 3.39 percent. This is a 42.5 percent decrease over losses of $(0.40) per share
Benzinga Insights

Tue May 12, 2026

Earnings Scheduled For May 12, 2026

Morgan Stanley

Thu Aug 13, 16:14

hold

confirm

Advanced Data Unlock

TWST $124.44 USD

ALAB $312.28 USD

AAPL $320.94 USD

NVTS $11.76 USD

TSLA $353.20 USD

SNOW $337.78 USD

LLY $1,143.03 USD